75 results about "Pharmacotherapy" patented technology

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

Disclosed are methods of improving treatment adherence and compliance after discontinuation of incretin-based therapies, such as GLP-1 and / or GIP agonists, using pharmacotherapies comprising the disclosed therapeutic compounds and combinations. In some aspects, methods include treatment of psychological factors affecting other medical conditions (PFAOMC) following the administration of incretin-based therapies to treat obesity or hyperglycemia, and related disorders. In some aspects, disclosed pharmacotherapies for use in the methods include agents that modulate monoaminergic neurotransmission, administered alone or together, such as in disclosed combinations having advantageous synergistic effects.

A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor(s) determining that a trigger event related to a patient, wherein the patient record comprises an order for a current drug regimen, has occurred in an electronic health record (EHR) system communicatively coupled to the one or more processors. The processor obtains descriptive information relating to a patient. The processor selects a pharmacokinetic model. The processor applies the pharmacokinetic model and utilizes the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection. The processor generates rankings for the drug therapies and determines if the current drug regimen comprises a probability above a threshold. The processor generates a new order.

Provided herein is a bioengineering and machine learning framework for complex tissue development, which can be implemented for the identification and / or assessment of gene and / or drug therapies.

Various methods and systems for efficiently providing pharmacogenetic guidelines is disclosed. A drug prescription and a patient genotype can be analyzed to provide a drug therapy recommendation. The analysis can include comparing the patient genotype and the drug name to a drug profile database, a molecular biomarker database, hospital drug reaction records and omics databases, and calculating the patient response to the drug.

The invention relates to an intelligent electrode slice medicine penetration physiotherapy system capable of adaptively adjusting skin resistance. The system comprises an acquisition module used for performing real-time electrical parameter acquisition and electric field response measurement on a contact interface area of an intelligent electrode slice to obtain electrical parameter distribution data and electric field response distribution data; the characteristic analysis module is used for converting the electrical parameter distribution data into a first characteristic spectrum and converting the electric field response distribution data into a second characteristic spectrum to obtain interface characteristic data; the state classification module is used for performing interface state classification operation through a machine learning model of adaptive parameter adjustment to obtain an interface state classification result; the adjusting module is used for carrying out output power adjustment and substance release control on the intelligent electrode plate to obtain a predicted transmission current; and the parameter optimization module is used for outputting working current meeting conditions. According to the invention, the energy consumption is reduced, the material transmission efficiency is improved, and the material migration depth control precision is also improved.

Disclosed are pharmaceutical preparations comprising bromantane or an analogue of bromantane, and methods of using said preparations for pharmacotherapy to alleviate withdrawal syndrome and prevent relapse in the treatment of stimulant use disorder, to transition patients off medications that have abuse or addiction liabilities, or to facilitate extinction learning in the treatment of mental disorders.

Exemplary light control devices and methods provide a regional variation of visual information and sampling (“V-VIS”) of an ocular field of view that improves or stabilizes vision, ameliorates a visual symptom, reduces the rate of vision loss, or reduces the progression of an ophthalmic or neurologic condition, disease, injury or disorder. The V-VIS devices and methods generate a moving aperture effect anterior to a retina that samples and delivers to the retina environmental light from an ocular field of view at a sampling rate between 50 hertz and 50 kilohertz. Certain of these V-VIS devices and methods may be combined with augmented or virtual reality, vision measurement, vision monitoring, or other therapies including, but not limited to, pharmacological, gene, retinal replacement and stem cell therapies.

The present application relates to the field of medicinal chemistry and pharmacotherapy, and in particular to a class of bazedoxifene and its preparation method and application. The bazedoxifene derivative is used for gp130 small molecule inhibitor, the compound is a compound shown in formula (I), or a pharmaceutically acceptable salt or ester thereof, and relates to the application of tumor-related activity and the like, in particular the application in preparing drugs for preventing and / or treating diseases related to tumors, especially colorectal cancer.

FIELD: neurology; psychiatry.SUBSTANCE: used as a non-pharmacological therapy for autism spectrum disorders in children. The method includes a set of procedures: interval hypoxic-hyperoxic training (HHT), hyperbaric oxygenation and ozone therapy. HHT consists of alternating inhalations of a hypoxic mixture with an oxygen content of 9 to 16 vol.% and a hyperoxic mixture with an oxygen content of 32 to 40 vol.% for a total duration of 45-50 minutes under the control of cardiovascular system parameters. Hyperbaric oxygenation is performed in a pressure chamber under a pressure of 1.3 atmospheres of 100% oxygen mixture, flow of 10 liters per minute, for 45 minutes using a mask. Ozone therapy is performed by rectal insufflation with an ozone-oxygen mixture with an ozone concentration of 85 μg / ml in a volume of 20–30 ml or by intravenous administration of a physiological solution enriched with ozone with an ozone concentration of 85 μg / ml at a rate of 200 ml per 100 ml of physiological solution. The procedures are carried out daily for 12 days.EFFECT: method is effective and has a positive impact on the patient’s condition.1 cl, 1 dwg, 3 ex

The present application relates to a kind of pterostilbene piperidine amide derivatives, its preparation method and medical use, belong to the field of medicinal chemistry and pharmacotherapy.The present application uses pterostilbene as raw material, designs, synthesizes a series of pterostilbene piperidine amide compounds with new structure, and its structure is characterized.The method used in the present application to prepare these compounds has the characteristics of easy-to-get raw material, simple operation and high yield, and can quickly synthesize target compounds.Compared with pterostilbene, the pterostilbene piperidine amide derivatives provided in the present application have significant cell proliferation inhibitory effect on tumor cells.

The present application belongs to the field of medicinal chemistry and pharmacotherapy, and particularly relates to a chalcone mannich base compound, a pharmaceutical composition and a preparation method and application thereof. The present application takes paeonol as a raw material, and obtains corresponding 3-substituted and 5-amino-methyl-substituted paeonol mannich base through mannich reaction of paeonol, polyoxymethylene and different organic amines. After the 3-substituted and 5-substituted paeonol mannich base is separated through column chromatography, the chalcone mannich base compound is obtained through Claisen-Schmidt reaction of the 3-substituted and 5-substituted paeonol mannich base and benzaldehyde containing different substituents. Experiments prove that the chalcone mannich base compound improves the physical and chemical properties of the chalcone mannich base and improves the drug efficacy, can solve the problem of poor water solubility, and has good anti-tumor cell proliferation activity.

The present embodiments relate to a multimodal cryptographic bio-human machine interface (“CB-HMI”), which seamlessly translates the user's touch-based entries into encrypted biochemical, biophysical, and biometric indices. The CB-HMI features thin hydrogel-coated chemical sensors and inference algorithms to non-invasively and inconspicuously acquire biochemical indices such as circulating molecules that partition onto the skin (here, ethanol and acetaminophen). Additionally, the CB-HMI hosts physical sensors and associated algorithms to simultaneously acquire the user's heart rate, blood oxygen level, and fingerprint minutiae pattern. Additional or alternative embodiments include a touch-based non-invasive monitoring solution for lithium pharmacotherapy management. The system is constructed based on a thin organohydrogel-coated lithium ion-selective electrode (TOH-ISE), where the TOH coating was engineered to render stabilized conditions for sensing. In particular, by adopting a water glycerol bi-solvent matrix, the gel features antidehydration property, rendering a controlled micro-environment for the ISE to condition and minimized the signal drift.

Recently, we have introduced 3D-micro-patterned pharmaceutical dosage forms for enhancing the efficacy, safety, convenience, and cost-effectiveness of drug therapies. Presented herein is an apparatus for the manufacture of such dosage forms. The apparatus comprises at least a first extruder and at least a second extruder. The first extruder comprises an extruder channel having an exit port with a valve mated to an input port of a second extruder. Said second extruder comprises a translatable piston for extruding plasticized fiber at controlled speed. The apparatus further comprises a stage movable at the controlled speed of the extruded fiber for depositing said fiber to a three dimensional structural framework.

A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the one or more processors, a list comprising one or more pathogens consistent with the information, the processor then obtaining a first indication designating at least one pathogen from the list comprising one or more pathogens and based on at the obtaining of the least one pathogen, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen. The method also includes the processor obtaining, descriptive information relating to a patient and based on the one or more drug therapies, selecting a pharmacokinetic model and the processor applying the pharmacokinetic model and utilizing the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection.

Provided are methods for preventing or delaying the need for surgical intervention in a patient having familial adenomatous polyposis (FAP) and an at least partially intact lower gastrointestinal tract. Also provided are methods for preventing or delaying the formation of neoplasia and / or cancer in a patient having FAP. The methods comprise administering an effective amount of a pharmaceutical therapy that comprises eflornithine and sulindac to a patient having FAP and an intact lower gastrointestinal tract.

The invention discloses a portable frequency-adjustable transcranial magnetic stimulation system and a stimulation method thereof. The system comprises an application program, a central control system and an intervention module, wherein the application program, the central control system and the intervention module are arranged in portable insomnia therapeutic equipment; the application program and the intervention module are both connected with the central control system. According to the invention, accurate matching with human body natural slow wave rhythm (Delta wave 1-4Hz and Theta wave 4-8Hz) is realized by releasing 1-8Hz Gamma low-frequency magnetic pulse waves capable of inhibiting excessive activity through control, slow wave synchronism is enhanced through frequency-phase resonance of magnetic field-neural oscillation, sleep is improved, and an instantaneous alternating magnetic field is generated to penetrate through skull to act on cerebral cortex, so that sleep quality is improved. Compared with a traditional medicine therapy, an invasive therapy and a non-invasive therapy, the side effect is smaller, the risk is lower, sleep can be further improved by playing soothing music, and the sleep neural circuit can be conveniently regulated and controlled at home to conveniently improve insomnia.

Methods and compounds to therapeutically treat a molecular target to counteract circuit adaptations of long-term opioid use that are associated with a functional disability and negative affect in both CBP−O (chronic back pain managed without opioids) and CBP+O (chronic back pain managed with opioids).

A method includes providing one of electrical therapy or drug therapy to a recipient to treat a condition of the recipient, monitoring an efficacy of the provided electrical therapy or drug therapy in treating the condition of the recipient, and controlling the other of the electrical therapy or the drug therapy based on the monitoring.

The invention provides a formula and method for treating nodules and cysts of all organs and multiple parts of a human body, and relates to the technical field of treatment of nodules and cysts of all organs and multiple parts of the human body, the formula is prepared by mixing the following materials: 10-15 g of tangerine pith, 10-15 g of rhizoma pinellinae praeparata and 10-15 g of poria cocos. The effect of treating nodules and cysts of various organs and multiple parts of a human body is obviously improved. And the formula is customized in a personalized manner, so that each patient can obtain the optimal medication scheme. The extraction efficiency and purity of the effective components are improved, and the high efficiency of the medicine is ensured. The bioavailability of the medicine is greatly improved and the medicine effect is obviously enhanced by nanocrystallization treatment and an intelligent preparation process. Pathological tissues are effectively damaged by modern non-drug therapies such as high-intensity focused ultrasound (HIFU) treatment and the like, the comprehensive effect is better in combination with traditional Chinese medicine treatment, the treatment effect is remarkably improved, the treatment period is shortened, and the compliance and satisfaction of patients are improved.

Pharmacological or gene inactivation of MAGL reduces neuroinflammation and neuropathology in AD animal models. However, global MAGL inactivation induces functional tolerance of CB1R, which reduces the effectiveness of drug therapy. Evidence has shown that selective inactivation of MAGL in astrocytes rather than neurons reduces neuropathological and synaptic and cognitive disorders in TBI. Specifically, results show that AD neuropathology is weakened by inactivation of the astrocyte MAGL, and LTP, spatial learning and memory deterioration of AD animals are prevented. This shows that the neuroprotection effect of global MAGL inactivation is mainly caused by limiting the degradation of 2-AG in astrocytes rather than neurons. Thus, the selective inactivation of the astrocyte MAGL provides a better therapeutic outcome for AD because this minimizes the potential side effects arising from the global inactivation-induced disruption of 2-AG degradation in neurons and other peripheral tissues. For this purpose, an AAV-mediated gene silencing method for selectively knocking out MAGL in astrocytes is proposed.

Disclosed are methods to treat patients with AFib by monitoring their heart rhythm to determine the presence and / or the number of episodes of long duration AFib, and optionally the extent of AFib burden. Patients who meet threshold requirements are qualified for the treatment of AFib with a dosage of budiodarone. Patient monitoring is continued in order confirm that the patient is and remains responsive to budiodarone therapy including dose adjusting the patient to achieve such therapy. Subsequently, monitoring is continued to confirm that the patient remains responsive. These methods allow for treatment of the AFib and, correspondingly, reduce or delay the risk of stroke and / or congestive heart failure in the treated patient.

The invention discloses pine-soot ink moxibustion as well as a preparation method and a use method thereof, and relates to the technical field of traditional Chinese medicine moxibustion therapy. Comprising the following raw materials: pine-soot ink, tourmaline powder, radix aconiti preparata, semen strychni preparata, sanguisorba officinalis, rhizoma corydalis, pseudo-ginseng, angelica sinensis, safflower carthamus, ligusticum wallichii, radix saposhnikoviae, gastrodia elata, frankincense, earthworm, herba epimedii, dogwood, lucid ganoderma, astragalus membranaceus, gynostemma pentaphyllum, artificial musk, wintergreen oil, borneol and beautifying wax. According to the pine-soot ink moxibustion and the preparation method and the use method thereof, the pine-soot ink is used as a substrate, the tourmaline powder is compounded, and a raw material system of multiple traditional Chinese medicines is selected, so that the product not only has the hot compress and pharmacodynamic permeation functions of the traditional Chinese medicines, but also has the adsorption characteristic of the pine-soot ink and the physical effects of negative ion release and far infrared effect generation of tourmaline; multiple synergy of a drug therapy and a physical therapy is realized, so that better health-care effects of relaxing tendons and activating collaterals, dispelling cold and removing dampness and relieving bone and joint pain are achieved.

A method for developing novel drug therapies utilizing properties of existing drug therapies, the method comprising the steps of: developing a novel therapeutic mathematical model of a target biological network and synthesizing a drug therapy based on the novel therapeutic mathematical model. The novel therapeutic mathematical model is capable of generating novel therapeutic time-course progressions, which include time-course progression features found in existing therapeutic time-course progressions of existing therapeutic mathematical models of the target biological network. The time-course progression features can be correlated with the outcomes of the target biological network. Each new therapeutic intervention constant can be used to synthesize a drug regimen, and these drug regimens collectively constitute the novel drug therapy.

A system for training medical providers in obesity management and obesity-related comorbidities includes a user device presenting a conversational interface to a medical provider, an application server managing user sessions, a database server storing user data including course completion records and clinical performance audits, and a learning management system server delivering educational modules based on established competencies. An artificial intelligence server processes queries from the medical provider and provides personalized medical advice using a large language model trained on obesity-related medical content including obesity physiology, pharmacotherapy, and patient management. The artificial intelligence server receives outcome information related to patient health metrics following the personalized medical advice and retrains the large language model based on the outcome information. A performance audit system monitors clinical documentation, prescribing patterns, and patient outcomes of the medical provider to ensure ongoing compliance and performance improvements.

A pharmaceutical composition for treating obsessive-compulsive disorder is provided. The present invention relates to (1) a pharmaceutical composition comprising a dopamine D1 receptor agonist as an effective ingredient for treating obsessive-compulsive disorder, and / or (2) a pharmaceutical composition comprising a dopamine D1 and D2 receptor stimulator, which is administered in combination with a dopamine D2 receptor inhibitor for the purpose of stimulating the dopamine D1 receptor in the striatum, and / or (3) a pharmaceutical composition comprising a dopamine D2 receptor inhibitor, which is administered in combination with a dopamine D1 and D2 receptor stimulator.

The present invention provides a selective TYK2 inhibitor compound, its preparation method, and its application, belonging to the technical fields of medicinal chemistry and pharmacotherapy. The present invention provides a novel structural aryl pyrimidine amine compound with good safety and excellent TYK2 and JAK inhibitory activity, providing a new option for the preparation of drugs for the prevention or treatment of autoimmune diseases.

The present invention relates to the use of the GLP-1 receptor agonist semeglutide in a pharmaceutical therapy for the treatment of ejection fraction retention heart failure (HFpEF).

Patients suffering from rhinitis and rhinosinusitis often experience symptoms such as nasal discharge, congestion, sniffles, and excess phlegm secretion. These symptoms can cause a feeling of impaired airflow, loss of patency, and uncomfortable breathing. In this context, a treatment method is proposed to alleviate these signs and symptoms. The drug target is the TRPM8 receptor on nerve fibers of the ostiomeatal complex. The active ingredient, a TRPM8 agonist, is delivered using an electronically controlled nebulizer that produces a vigorous air plume of defined particle sizes, which prevents entry into the lungs. The quantity of phlegm expelled from the nasal passage is used as an index of anti-inflammatory effectiveness. The optimized drug candidates for delivery and therapy are from a group of p-menthanecarboxamides. Preferred embodiments of these include the p-menthane amino acid esters: GlyOnPr, GlyOiPr, D-Ala-OnPr, and D-Ala-OiPr, delivered as a liquid suspension or solution at 0.1 to 1% (1 to 10 mg / mL), 0.5 to 0.8 mL per nostril over 3 to 5 seconds, using a nebulizer. This regimen, administered three times per day for three to five days, will help the patient manage and control their nasal congestion and phlegm secretion, and sleep better at night. The preferred embodiments delivered into the nasal cavity create a sense of cool breathing, refreshing coolness, and a feeling of negative heat flux, like an air conditioner in the nose. The secretion of phlegm is clearly decreased, as measured with a top-loading balance. This pharmacological treatment for patients with nasal inflammation has the potential to alter the course of rhino-disorders permanently.

The application belongs to the technical field of pharmacotherapy, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing acute kidney injury caused by kidney ischemia-reperfusion. The ganoderic acid A can inhibit apoptosis, pyroptosis and necrosis in acute kidney injury induced by kidney ischemia-reperfusion, and reduce the levels of creatinine and urea nitrogen, which are kidney function indexes. The application first discovers that the ganoderic acid A has a protective effect on kidney ischemia-reperfusion, and the mechanism is related to inhibition of pan-apoptosis (PANoptosis) of renal tubular epithelial cells, which indicates that the ganoderic acid A has a prospect of developing into a medicine for preventing acute kidney injury caused by kidney ischemia-reperfusion.